Abstract
A liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been executed and validated to quantify cefuroxime axetil in the presence of its degradation products. Cefuroxime axetil and its degradation products were resolved with time programmed gradient elution on Eclipse XDB-C18 column (100 × 4.6 mm, 3.5 µm, Agilent, USA) kept at 40 °C. Under negative ion electrospray ionization, the analyte was quantified and monitored on a triple quadrupole mass spectrometer using multiple reaction monitoring scanning mode. Good results concerning the different validation parameters of the cefuroxime axetil were collected. The linearity was established in the range of 1.0–1000 ng mL−1 and showed an excellent correlation coefficient value (r ≥ 0.999). A comprehensive stress testing of cefuroxime axetil has been implemented according to the International Conference on Harmonization guidelines Q1A (R2).
Similar content being viewed by others
References
S. Ahuja, Impurities Evaluation of Pharmaceuticals (Informa Healthcare, 1998), p. 17
K.C. Waterman, R.C. Adami, J.Y. Hong, Handbook of Isolation and Characterization of Impurities, in Pharmaceuticals. ed. by S. Ahuja, K.M. Alsante (Academic Press, New York, 2004), pp. 75–88
FDA, Guidance for Industry Q3A Impurities in New Drug Substances (2008). https://www.fda.gov/media/71727/download. Accessed 26 July 2019
I. Ivana, Z. Ljiljana, Z. Mira, J. Chromatogr. A 1119, 209 (2006)
A. Martin, J. Delgado, W. Remers, Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 10th edn. (Lippincott-Raven Publishers, New York, 1998), pp. 318–334
W.O. Foye, T.L. Lemke, D.A. Williams, Foye’s Principles of Medicinal Chemistry, 7th edn. (Lippincott Williams & Wilkins, Philadelphia, 2012), p. 1059
N.J. Snyder, L.B. Tabas, D.M. Berry, D.C. Duckworth, D.O. Spry, A.H. Dantzig, Antimicrob. Agents Chemother. 41, 1649 (1997)
Cefuroxime Axetil in British Pharmacopoeia (Stationery Office, London, 2013) p. 294
A.F.M. El Walily, A.A.K. Gazy, S.F. Belal, E.F. Khamis, Spectrosc. Lett. 33, 931 (2000)
J. Murillo, J. Lemus, L. Garcia, J. Pharm. Biomed. Anal. 12, 875 (1994)
M.M. Ayad, A.A. Shalaby, H.E. Abdellatef, H.M. Elsaid, J. Pharm. Biomed. Anal. 18, 975 (1999)
I. Al-Momani, J. Pharm. Biomed. Anal. 25, 751 (2001)
M.V. Shinde, S.A. Pishawikar, H.N. More, Indian J. Pharm. Sci. 70, 249 (2008)
J. Krzek, M. Dąbrowska-Tylka, Chromatographia 58, 231 (2003)
M. Dabrowska, J. Krzek, J. AOAC Int. 93, 771 (2010)
P.N. Ranjane, S.V. Gandhi, S.S. Kadukar, K.G. Bothara, J. Chromatogr. Sci. 48, 26 (2010)
D.K. Singh, G. Maheshwari, Biomed. Chromatogr. 24, 1084 (2010)
K.C. Sung, Y.C. Changchein, P.C. Chen, C.L. Lu, R.Y. Han, Y.Y. Lin, J. Food Drug Anal. 7, 45 (1999)
N.O. Can, G. Altiokka, H.Y. Aboul-Enein, Anal. Chim. Acta 576, 246 (2006)
M.S. Al-Said, K.I. Al-Khamis, E.M. Niazy, Y.M. El-Sayed, K.A. Al-Rashood, S. Al-Bella, M.A. Al-Yamani, T.A. Al-Najjar, S.M. Alam, R. Dham, Q. Zaman Qumaruzaman, Biopharm. Drug Dispos. 21, 205 (2000)
K.D. Altria, M.M. Rogan, J. Pharm. Biomed. Anal. 8, 1005 (1990)
A.A.M.J. Finn, A. Straughn, M. Meyer, J. Chubb, Biopharm. Drug Dispos. 8, 519 (1987)
I. Gonzalez-Hernandez, H. Jung-Cook, A. Sotelo, Int. J. Pharm. Pharm. Sci. 11, 9 (2008)
A. Jelińska, I. Dudzińska, M. Zajac, I. Oszczapowicz, W. Krzewski, Acta Pol. Pharm. 62, 183 (2005)
G.D. Mendes, A. Borges, L. de Cássia Val, A.K. Patni, S. Reyar, T. Monif, D. Sereno, A.M.M. Orellana, G. De Nucci, Arzneimittelforschung 60, 101 (2010)
C. Pistos, S. Michalea, M. Kalovidouris, G. Kontopoulos, M. Georgarakis, Int. J. Clin. Pharm. 42, 367 (2004)
P.N. Ranjane, S.V. Gandhi, S.S. Kadukar, S.S. Ranher, Chin. J. Chromatogr. 26, 763 (2008)
N. Rojanasthien, C. Boonchaliew, B. Kumsorn, C. Sangdee, J. Med. Assoc. Thail. 86, 1063 (2003)
D.K. Sommers, M. Van Wyk, P.E. Williams, S.M. Harding, Antimicrob. Agents Chemother. 25, 344 (1984)
S. Vasu, C. Adithan, C.H. Shashindran, A. Mohammed, Indian J. Med. Res. 112, 104 (2000)
M.T. Rosseel, R. Peleman, H. Van Hoorebeke, R.A. Pauwels, J. Chromatogr. B 689, 438 (1997)
T.H. Tsai, F.C. Cheng, K.C. Chen, Y.F. Chen, C.F. Chen, J. Chromatogr. B 735, 25 (1999)
P. Ruiz-Carretero, A. Nacher, M. Merino-Sanjuan, V.G. Casabo, Int. J. Pharm. 202, 89 (2000)
W.A. Moats, R.D. Romanowski, J. Chromatogr. A 812, 237 (1998)
M.A. Barrett, M.J. Lawrence, H.C. Jackson, A.J. Hutt, A.B. Lansley, Eur. J. Pharm. Biopharm. 4, S195 (1996)
G. Pajchel, S. Tyski, J. Chromatogr. A 895, 27 (2000)
Y. Mrestani, R. Neubert, J. Schiewe, A. Härtl, J. Chromatogr. B 690, 321 (1997)
Y. Mrestani, R.H. Neubert, A. Härtl, J. Wohlrab, Anal. Chim. Acta 349, 207 (1997)
M. Zając, A. Jelińska, L. Dobrowolski, I. Oszczapowicz, J. Pharm. Biomed. Anal. 32, 1181 (2003)
H. Zegota, M. Koprowski, A. Zegota, Radiat. Phys. Chem. 43, 343 (1994)
L.M. Galanti, J.D. Hecq, D. Vanbeckbergen, J. Jamart, J. Clin. Pharm. Ther. 21, 185 (1996)
M.A. Faouzi, T. Dine, M. Luyckx, B. Gressier, C. Brunet, F. Goudaliez, M.L. Mallevais, M. Cazin, J.C. Cazin, Pharmazie 49, 425 (1994)
A. Barnes, J. Clin. Pharm. Ther. 15, 187 (1990)
H. Fabre, H. Ibork, D. Lerner, J. Pharm. Sci. 83, 553 (1994)
M.W. Nassar, F.M. Salamaa, M.M.S. El-Din, K.A. Attia, M.Y. Kaddah, AJAC. 2, 332 (2011)
ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products (2003). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf. Accessed 16 June 2019
Technologies, A. ZORBAX Eclipse XDB. https://www.agilent.com/en-us/products/liquid-chromatography/lc-columns/small-molecule-separations/zorbax-eclipse-xdb#literature. Accessed 19 April 2018
M. Li, Organic Chemistry of Drug Degradation (Royal Society of Chemistry, 2012), pp.165–190
C.C. Chan, Y.C. Lee, H. Lam, X.M. Zhang, Analytical Method Validation and Instrument Performance Verification (Wiley, Hoboken, 2004), pp. 27–49
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sharaf El-Din, M.M.K., Nassar, M.W.I., Attia, K.A.M. et al. Liquid chromatography–tandem mass spectrometry method for the determination of cefuroxime axetil diastereoisomers: application to stability-indicating method. J IRAN CHEM SOC 18, 2505–2515 (2021). https://doi.org/10.1007/s13738-021-02210-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13738-021-02210-2